From the article:
After examining the best available scientific evidence, Morgentaler and colleagues – who included experts with specialties in urology, endocrinology, diabetes, internal medicine, and basic science research – agreed on the following:
– TD [testosterone deficiency] is a well-established, clinically significant medical condition that negatively affects male sexuality, reproduction, general health and quality of life.
– Symptoms and signs of TD occur as a result of low levels of testosterone and may benefit from treatment regardless of whether there is an identified underlying origin.
– TD is a global public health concern.
– Testosterone therapy for men with TD is effective, rational, and evidence-based.
– There is no testosterone concentration threshold that reliably distinguishes those who will respond to treatment from those who will not.
– There is no scientific basis for any age-specific recommendations against the use of testosterone therapy in adult males.
– The evidence does not support increased risks of cardiovascular events with testosterone therapy.
– The evidence does not support increased risk of prostate cancer with testosterone therapy.
– The evidence supports a major research initiative to explore possible benefits of testosterone therapy for cardiometabolic disease, including diabetes.
“It will be surprising to those unfamiliar with the literature to learn how weak the evidence is supporting the alleged risks of cardiovascular disease and prostate cancer,” said Michael Zitzmann, MD, vice-chair of the conference and a Professor in the Centre for Reproductive Medicine and Andrology at the University of Muenster in Germany. “Indeed, there is substantial data suggesting there may actually be cardio-protective benefits of testosterone therapy.”